Genmab — Februar 2019

[Hugininvest]

Lige en til fe søvnige: Goldmann Sachs cheføkonom siger at det tyder på at verdensøkonomien har bundet for denne gang ! Det peger op! Øh - stakkels alle dem der gik og ventede på en nedtur. Bussen kørte måske forbi dem

[E_L]

nice ranking by Institutional Investor https://twitter.com/RachelGravesen/status/1100844183143809024 , and I honestly have to say, well deserved, they have improved soo much over the last few years

[Helge_LarsenPI-redaktør]

Så fortjent.

[Helge_LarsenPI-redaktør]

Af hjertet tak for donation: http://www.proinvestor.com/network

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[transalp]

Go morgen:)

[Solsen]

Yderligere 500.000 warrant på dagsorden - men muligt buy back på ca 1 mio aktier, Så forhåbentlig er udvandingen ved at stoppe.

[bibob]

God morgen. :-). Det ville være rart Solsen.

[JKY_VH]

enig, det er den helt rigtige vej at gå.

[E_L]

Rachel Gravesen‏ @RachelGravesen

Unlikely that daratumumab SC formulation will be submitted under RTOR as that program is only for sBLAs and the SC version will need to be a full BLA as it is a new formulation.

09:33 - 28 feb. 2019 vanuit Princeton Junction, NJ https://twitter.com/RachelGravesen/status/1101037575605764096

[peter12]

Ok aktier for nominelt 500000 kr svarer til 500000 aktier ? Det lyder ikke dumt

[Bulder]

Of even more importance - I think - is whether Columba can form the basis of an approval i all treatment lines or we'll have to wait for the combo data. That Columba data came this quickly is as good as a RTOR.

[Hen]

GENMAB/BOFA-ML: HÆVER ANBEFALING TIL NEUTRAL
Bank of America-Merrill Lynch har løftet sin anbefaling af Genmab til neutral fra underperform, rapporterer Bloomberg News.
Opjusteringen kommer oven på en god uge for Genmab-aktien, der sidste torsdag præsenterede overraskende stærke forventninger til 2019 og i denne uge har offentliggjort positive resultater fra et fase 3-studie med en mere patientvenlig version af kræftmidlet Darzalex.

[Hen]

Den nye version kan tages via sprøjte med en behandlingstid på bare omkring tre minutter, mens den nuværende version af Darzalex tages intravenøst over tre en halv time.
Aktien ligger torsdag yderligere 1,5 pct. højere i 1143 kr. og er over den seneste seks børsdage steget sammenlagt 13,4 pct.
/ritzau/FINANS

[E_L]

@Bulder yes, that is the big question. My guess is that we will have to wait for that data, but just as the data for Columba came so quick, I am now hoping for the additional data to also come quicker as expected.

[Vester]

@Bulder har du stillet spm til Winkel ang dette?

[E_L]

preliminary completion dates for Columba and MMY2040 are very similar, even though the latter started later

[E_L]

and we have been told a few times 'recruitment is going very fast'

[Bulder]

yes, I have a Q about this.

[E_L]

@Vester , this is what Jan said last Feb Q&A: Q: In january you started a “Study to evaluate Subcutaneous Daratumumab in
combination with Standard Multiple Myeloma Treatment Regimens”, which is a Phase
2. You already have the Phase 3 SC vs IV study; could these 2 clinical trials be the
basis for an overall approval of SC in all lines and settings?
Jan Van de Winkel: This is a good thought.